Quantcast

Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)


Shutterstock photo

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Aerie Pharmaceuticals, Inc. AERI , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in AERI.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen three estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of $2.54 a share a month ago to its current level of a loss of $3.42.

Also, for the current quarter, Aerie Pharmaceuticals has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of $1.44 a share from a loss of 67 cents over the past 30 days.  

The stock also has seen some pretty dismal trading lately, as the share price has dropped 9% in the past month.

Aerie Pharmaceuticals, Inc. Price and Consensus

Aerie Pharmaceuticals, Inc. Price and Consensus | Aerie Pharmaceuticals, Inc. Quote

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait.

If you are still interested in the Medical - Drugs industry, you may instead consider a better-ranked stock - Akebia Therapeutics, Inc. AKBA . The stock currently holds a Zacks Rank #2 (Buy) and may be a better selection at this time. You can see  the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

Zacks' Hidden Trades

While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?

Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.

Click here for Zacks' secret trade>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report

Aerie Pharmaceuticals, Inc. (AERI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Earnings , Investing Ideas , Stocks
Referenced Symbols: AKBA , AERI


More from Zacks.com

Subscribe






Zacks.com
Contributor:

Zacks.com

Equity Research








Research Brokers before you trade

Want to trade FX?





Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com